Exelixis, Inc.  

(Public, NASDAQ:EXEL)   Watch this stock  
Find more results for EXEL
6.14
+0.41 (7.16%)
Real-time:   3:51PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.76 - 6.31
52 week 1.26 - 6.38
Open 5.77
Vol / Avg. 5.63M/8.13M
Mkt cap 1.26B
P/E     -
Div/yield     -
EPS -1.17
Shares 221.02M
Beta 2.57
Inst. own 55%
Aug 11, 2015
Q2 2015 Exelixis Inc Earnings Call - 5:00PM EDT - Add to calendar
Aug 11, 2015
Q2 2015 Exelixis Inc Earnings Release - 4:00PM EDT - Add to calendar
Jul 20, 2015
Exelixis Inc Conference Call to discuss the Results of Clinical Trial - Webcast
May 27, 2015
Exelixis Inc Annual Shareholders Meeting
May 12, 2015
Exelixis Inc at Bank of America Merrill Lynch Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -374.63% -1069.42%
Operating margin -242.44% -893.86%
EBITD margin - -854.00%
Return on average assets -46.18% -64.61%
Return on average equity - -
Employees 98 -
CDP Score - -

Address

210 E Grand Ave
SOUTH SAN FRANCISCO, CA 94080-4811
United States - Map
+1-650-8377000 (Phone)
+1-650-8378300 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Company's other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Michael M. Morrissey Ph.D. President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Christopher J. Senner Chief Financial Officer, Executive Vice President
Age: 48
Bio & Compensation  - Reuters
Peter Lamb Ph.D. Executive Vice President - Discovery Research, Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Jeffrey J Hessekiel Executive Vice President, General Counsel
Age: 45
Bio & Compensation  - Reuters
Gisela M. Schwab M.D. Executive Vice President, Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Pamela A. Simonton J.D. Executive Vice President
Age: 64
Bio & Compensation  - Reuters
Deborah Burke Senior Vice President - Finance, Controller
Age: 59
Bio & Compensation  - Reuters
Charles M. Cohen Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Carl B. Feldbaum Esq Independent Director
Age: 71
Bio & Compensation  - Reuters